MPM Oncology Impact Management »

Allogene Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Allogene Therapeutics (ALLO) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Allogene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Allogene Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allogene Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $5.5M 2.2M 2.44

More positions owned by MPM Oncology Impact Management

DBV Technologies S A Sponsored Ads (DBVT)
Cullinan Therapeutics Common (CGEM)
Aktis Oncology Common
Liquidia Corporation Common (LQDA)
Alumis Common (ALMS)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Corcept Therapeutics Common (CORT)
Trevi Therapeutics Common (TRVI)
Dianthus Therapeutics Common (DNTH)
Xenon Pharmaceuticals Common (XENE)
MoonLake Immunotherapeutics Class A Ord (MLTX)
Travere Therapeutics Common (TVTX)
Evommune Common (EVMN)

View all positions for MPM Oncology Impact Management

Top funds holding Allogene Therapeutics

Pfizer
BlackRock
Tpg Gp A
Vanguard Group
PRIMECAP Management Company
Vanguard Capital Management
Citadel Advisors
Two Sigma Investments
Geode Capital Management
Frazier Life Sciences Management
Woodline Partners
Patient Square Capital
Millennium Management
Candriam Luxembourg S.C.A.
Wildcat Capital Management

View all funds holding Allogene Therapeutics